J&J Ready To Re-Balance? Guidant Deal Would Decrease Dependence On Rx
Executive Summary
Johnson & Johnson's proposed acquisition of Guidant will help the company restore the balance in its health care portfolio
You may also be interested in...
Biotech Exit Strategy Of Choice Is Acquisition, Not IPO, Investor Says
Venture capital firms are increasingly shaping biotech companies to look like acquisition prospects from the outset, rather than candidates for initial public offerings, according to one investor's analysis
Biotech Exit Strategy Of Choice Is Acquisition, Not IPO, Investor Says
Venture capital firms are increasingly shaping biotech companies to look like acquisition prospects from the outset, rather than candidates for initial public offerings, according to one investor's analysis
J&J Sees Rx Synergies In Guidant Deal; Big Buy Does Not Rule Out More Deals
J&J's acquisition of Guidant will open up new areas of opportunity for collaboration between the pharmaceutical, device and diagnostic operations of the company, CEO William Weldon declared during a Dec. 16 analysts conference call